MedTrace Logo

A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission

NCT03281304 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2023-03-21

Study results available
· View outcomes & findings →

Summary

This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.

Conditions

Interventions

DRUG

CP-690,500 5 mg

CP-690,550 5 mg tablet BID

DRUG

CP-690,550 10 mg

CP-690,550 10 mg tablet BID

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-16
Primary Completion
2020-02-14
Completion
2022-03-18
FDA Drug
Yes

Countries

  • United States
  • Belgium
  • Canada
  • Czechia
  • France
  • Germany
  • Hungary
  • Italy
  • Japan
  • Netherlands
  • New Zealand
  • Poland
  • Russia
  • Serbia
  • Slovakia
  • South Africa
  • South Korea
  • Spain
  • Ukraine
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03281304 on ClinicalTrials.gov